Searchable abstracts of presentations at key conferences in endocrinology

ea0040l5 | Endocrine cancer: in the light of recent molecular studies | ESEBEC2016

Endocrine cancer: in the light of recent molecular studies

Jarza¸b Barbara , Krajewska Jolanta

Endocrine cancer constitutes a term and simultaneously a definition of a type of cancer, that is common in American literature whereas so far absent in European nomenclature. Detailed analysis of scientific programs of European endocrinological and oncological congresses proves that also these societies do not mention this type of cancer. To change this unfavorable situation a new clinical platform called European Task Group for Endocrine Cancer (ETEC), working under the auspi...

ea0063p1161 | Thyroid 3 | ECE2019

Do patients with differentiated thyroid cancer (DTC) harboring TERT promoter mutation require a more intensive treatment and follow-up? – proposal of a prospective study

Samborski Konrad , Krajewska Jolanta , Rusinek Dagmara , Oczko-Wojciechowska Magdalena , Jarzęb Barbara

Introduction: The importance of telomerase reverse transcriptase promoter (TERTp) mutations in DTC is widely discussed. It has been demonstrated that the presence of TERTp mutations is associated with higher cancer aggressiveness, reflected by lymph node metastases, distant metastases, advanced tumor stage, recurrence, and even disease-specific mortality. Nevertheless, there is no clear evidence-based data demonstrating how to manage these patients. Therefore...

ea0049ep1420 | Thyroid (non-cancer) | ECE2017

Prognostic value of preoperative serum calcitonin concentration on primary surgery outcomes in medullary thyroid cancer

Gawlik Tomasz , Kukulska Aleksandra , Wygoda Zbigniew , Krajewska Jolanta , Stobiecka Ewa , Czarniecka Agnieszka , Jarzab Barbara

Calcitonin assessment in thyroid diseases is recommended when medullary thyroid cancer (MTC) is suspected in fine needle biopsy, as well as in ‘suspicious for a follicular neoplasm’ class, especially oxyphilic type, in patients with germinal RET proto-oncogene mutation and in nondiagnostic biopsy when no surgical treatment is planned. This assessment is also suggested before any planned thyroid surgery to exclude MTC. Beyond diagnosis confirmation it is also suggeste...

ea0049ep1441 | Thyroid (non-cancer) | ECE2017

Cooperation between an endocrine nurse, psychologist and physician and their mediating role in the care of depression in patients treated with multi kinase inhibitors due thyroid cancer

Rozanska Alina , Syska-Bielak Anna , Kraus Justyna , Ocieczek Malgorzata , Wojtyna Ewa , Krajewska Jolanta

The treatment with multi kinase inhibitors (MKI) under clinical trials due to advanced thyroid cancer (TC) may postpone moving on the patients with advanced disease to the palliative care stage. However, chronic and escalating somatic symptoms during the treatment may promote the appearance of depressive reactions. It can be expected that a cognitive image of the disease, as a collection of subjective beliefs concerning patient’s own illness and treatment, will be an impo...

ea0049ep1440 | Thyroid (non-cancer) | ECE2017

Management of treatment-related toxicity caused by multi kinase inhibitors administered due to advanced thyroid carcinoma

Krajewska Jolanta , Kukulska Aleksandra , Handkiewicz-Junak Daria , Paliczka-Cieslik Ewa , Olczyk Tomasz , Gawlik Tomasz , Ledwon Aleksandra , Michalik Barbara , Jarzab Barbara

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

ea0035p562 | Endocrine tumours and neoplasia | ECE2014

Consolidation treatment with somatoatatin analogues after radiopeptide therapy

Sygula Aleksandra , Handkiewicz-Junak Daria , Kotecka-Blicharz Agnieszka , Hasse-Lazar Kornelia , Jurecka-Lubieniecka Beata , Krajewska Jolanta , Jarzab Barbara

Background: Although neuroendocrine tumours (NET) constitute a very heterogeneous group, most of them express somatostatin receptors that enable treatment with somatostatin analogues(SA), which proved to be effective both as bio- or radiopeptide therapy. However, little is now about combining this two treatment modalities.The aim of our prospective study was to evaluate results of radiolabeled somatostatin analogues (PRRT) with or without long lasting ‘cold’ SA as co...

ea0035p832 | Pituitary Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Correlation of coexpression of pituitary genes in QPCR and microarray study in pituitary adenomas

Zebracka-Gala Jadwiga , Larysz Dawid , Pfeifer Aleksandra , Rudnik Adam , Krajewska Jolanta , Hasse-Lazar Kornelia , Kowalska Malgorzata , Bazowski Piotr , Jarzab Barbara

Introduction: Mechanism of pathogenesis of pituitary adenomas is still unknown. Gene expression differences in pituitary cells of different origin are not extensively described. Identification of genes specific for pituitary adenomas should enable better understanding of differences in their response to therapy, especially to radiotherapy.Aim: The aim of our study was to evaluate the correlation of coexpression of distinct pituitary adenoma genes based o...

ea0020p239 | Bone/Calcium | ECE2009

The results of cinacalcet therapy in patients with severe or refractory hypercalcemia due to primary hyperparathyroidism

Krajewska Jolanta , Paliczka-Cieslik Ewa , Krawczyk Aleksandra , Szpak-Ulczok Sylwia , Michalik Barbara , Hasse-Lazar Kornelia , Jurecka-Lubieniecka Beata

Refractory or severe hypercalcemia is important clinical problem as it can lead to serious complications such as arrhythmias, acute or chronic pancreatitis, gastric ulcer, water and electrolyte balance disturbances, osteoporosis, psychoses and even to hypercalcemic crisis. Most often it is diagnosed in parathyroid cancer (PC). It is also observed in benign primary hyperparathyroidism (HPTH) in case of difficulties with adenoma’s localization. Routinely treatment includes ...

ea0056gp226 | Thyroid Cancer - Diagnostics &amp; Treatments | ECE2018

Significant acceleration in dynamics of medullary thyroid cancer markers concentration – report of 26 cases

Gawlik Tomasz , Krajewska Jolanta , Kukulska Aleksandra , Wygoda Zbigniew , Szpak-Ulczok Sylwia , Krol Aleksandra , Puch Zbigniew , Jarzab Barbara

Calcitonin and carcinoembryonal antigen are biochemical markers of medullary thyroid carcinoma (MTC). Assessment of the dynamics of their serum concentration allow for calculation of their doubling times that are independent risk factors for overall survival and progression-free survival in MTC. It is generally accepted that the dynamics and the doubling times remain stable during follow-up.Aim: The aim of the study was to retrospectively verify the stab...

ea0037ep904 | Thyroid cancer | ECE2015

Adjuvant radioiodine (RAI) treatment reduces the risk of relapse in low advanced differentiated thyroid carcinoma (DTC)

Krajewska Jolanta , Jarzab Michal , Czarniecka Agnieszka , Kukulska Aleksandra , Handkiewicz-Junak Daria , Wygoda Zbigniew , Puch Zbigniew , Paliczka-Cieslik Ewa , Roskosz Jozef , Jarzab Barbara

The routine use of adjuvant RAI treatment in low-risk DTC remains controversial due to the lack of unequivocal evidences of its effectiveness in radically operated subjects. The aim of the study was a retrospective evaluation of long-term outcomes of combined DTC treatment to evaluate the impact of adjuvant RAI therapy in the low risk group. Primary hypothesis was: ‘if adjuvant RAI treatment was unnecessary, a delay in RAI administration would have no impact on long-term ...